Interesting. My view is it isn't even close to being forward. But my experience is not with penny stocks. Always Biotech, Pharma, Medical Device, and Healthcare Technology. And the ALRT price considering the services they are developing is crazy low. IMO, the issue with ALRT is their services/products are the first of kind...as such no one understands the value. They are not replacing anything........they are complementary. Whereas a new drug that is not even FDA approved may be deemed to have a sales potential of $500 million a year due to it's market category. And the company may not have ever had a single dollar of sales but the projected sales and earnings can generate $1 billion or more in market cap.